Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background and Purpose</h3><p>Previously, we discovered that activation of nucleotide-binding oligomerization domain 2 (NOD2) enhances platelet activation. We here investigated the antiplatelet and antithrombotic potential of GSK669, a NOD2 antagonist.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Experimental</h3><p>Approach</p><p>Effects of GSK669 on platelet functions, reactive oxygen species (ROS) and proinflammation cytokine generation were detected. NOD2-/- platelets were used to confirm GSK669 target. The interaction between GSK669 and glycoprotein VI (GPVI) was detected using surface plasmon resonance (SPR) spectroscopy. GPVI downstream signaling was examined by Western blot. The antithrombotic and antioxidative effects were investigated using mouse mesenteric arteriole thrombosis model and pulmonary embolism model.</p><p>Key Results</p><p>GSK669 significantly inhibits platelet proinflammatory cytokine release induced by muramyl dipeptide, platelet aggregation, ATP release, and ROS generation induced by collagen and collagen related peptide (CRP). Platelet spreading and clot retraction are also inhibited. GSK669 also decreases collagen-induced phosphorylation of Src, Syk, PLCγ2, and Akt. The antiplatelet effect of GSK669 is NOD2-independent and mediated by GPVI antagonism. Consistent with its antiplatelet activity as a GPVI antagonist, GSK669 inhibits platelet adhesion on collagen in flow condition. Notably, GSK669 inhibits mouse mesenteric arteriole thrombosis similarly to aspirin without bleeding. The antithrombotic effect of GSK669 is further confirmed in the pulmonary embolism model; decreased malonaldehyde (MDA) and increased superoxide dismutase (SOD) levels in mouse plasma reveal a significant antioxidant effect of GSK669.</p><p>Conclusion and Implications</p><p>Beyond its anti-inflammatory effect as a NOD2 antagonist, GSK669 is also an efficient and safe antiplatelet agent combined with antioxidant effect by targeting GPVI. An antiplatelet agent bearing antioxidative and anti-inflammatory activities without bleeding risk may have therapeutic advantage over current antiplatelet drugs for atherothrombosis.</p>

RGD and Scutellarin Conjugate (WK001) Targeting Platelet Glycoprotein IIb/IIIa Receptor Protects from Myocardial Ischemia/Reperfusion Injury: Synthesis, Characterization, and Bioactivity Evaluation

Ginsenoside-Rp3 inhibits platelet activation and thrombus formation by regulating MAPK and cyclic nucleotide signaling

Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent

Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus

Safety and Efficacy of a Platelet Glycoprotein Ib Inhibitor for Patients with Non‐st Segment Elevation Myocardial Infarction: A Phase Ib/IIa Study

Abstract 12438: Efficacy and Safety Evaluation of a Platelet Glycoprotein Ib Inhibitor for Patients with Non-ST Segment Elevation Myocardial Infarction

Glaucocalyxin A Inhibits Platelet Activation and Thrombus Formation Preferentially via GPVI Signaling Pathway

Efficient targeted anticoagulant with active RGD motif.

WY-14643, a novel antiplatelet and antithrombotic agent targeting the GPIbα receptor

Platelet glycoprotein receptor Ib blockade ameliorates experimental cerebral ischemia-reperfusion injury by strengthening the blood-brain barrier function and anti-thrombo-inflammatory property

A Novel Hirudin Derivative Characterized with Anti-Platelet Aggregations and Thrombin Inhibition.

Anti-thrombotic Effects Mediated by a Novel Dual-Target Peptide Inhibiting Both Platelet Aggregation and Thrombin Activity without Causing Bleeding

Ginkgetin effectively mitigates collagen and AA‐induced platelet activation via PLCγ2 but not cyclic nucleotide‐dependent pathway in human

Engineering Factor Xa Inhibitor with Multiple Platelet-Binding Sites Facilitates its Platelet Targeting

RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection

GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet GPVI

Selective binding of cationic fibrinogen-mimicking chitosan nanoparticles to activated platelets and efficient drug release for antithrombotic therapy

Targeting the RT loop of Src SH3 in Platelets Prevents Thrombosis without Compromising Hemostasis

Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities

Structure-guided Creation of AcAP5-derived and Platelet Targeted Factor Xa Inhibitors